<scp>CT</scp> ‐ <scp>P39</scp> Compared With Reference Omalizumab in Chronic Spontaneous Urticaria: Results From a Double‐Blind, Randomized, Active‐Controlled, Phase 3 StudySarbjit S. Saini, Clive Grattan, Marcus Maurer et al.|Allergy|2025Cited by 28
Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 studyChristian Buske, Michinori Ogura, Jin Seok Kim et al.|Blood Advances|2021Cited by 9